OverT Bio, a cell therapy company based in New York City, has announced it has received a $120,000 G-Rex Grant from ScaleReady™, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady™. The grant will support OverT Bio’s continued development of next-generation cell therapies for solid tumors, utilizing its innovative data-driven discovery platforms, OverTarget™ and OverTCR™.
OverT Bio, a New York City-based biotechnology company, has announced that it has been awarded a $120,000 G-Rex Grant from ScaleReady™, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady™. This grant is part of ScaleReady’s $20 million grant program, designed to advance the development and manufacturing of Cell and Gene Therapies (CGT). The funds will support OverT Bio’s efforts to develop next-generation cell therapies for solid tumors, utilizing its innovative OverTarget™ and OverTCR™ platforms.
Mat Legut, PhD, CEO of OverT Bio, expressed gratitude for the grant, stating, “We are pleased to receive ScaleReady’s support and their recognition of the potentially high impact our technology has to advance our shared mission of bringing new life-saving therapeutics to cancer patients. This grant, combined with access to newly developed GMP closed system products and ScaleReady’s expertise, will help us accelerate the development of our products, ensuring scalability and cost-effectiveness for these potential medicines.”
The G-Rex Grant is part of ScaleReady’s broader mission to support CGT development by offering significant, no-cost support to recipients. This enables faster optimization of cell manufacturing processes, ultimately helping to reduce both time and costs in bringing novel therapies to market. Josh Ludwig, Commercial Director of ScaleReady, emphasized the importance of the grant, stating, “Our support of OverT Bio is another example of how our G-Rex Grant Program facilitates the advancement of cell and gene-modified cell therapy. The G-Rex Grant Program aligns with ScaleReady’s mission to provide every CGT company with the resources to save time and money, while also building strong value propositions for continued investment.”
About OverT Bio
OverT Bio, Inc. is a biotechnology company focused on developing safe and effective cellular therapies for solid tumors. Using innovative pooled functional screening and synthetic genomics platforms—OverTarget™ and OverTCR™—the company is identifying new therapeutic targets and genetic enhancements in an unbiased, data-driven manner. This approach aims to deliver breakthrough medicines to cancer patients who are underserved by current treatment options.
About ScaleReady™
ScaleReady provides a G-Rex-centric manufacturing platform to advance cell and gene-modified cell therapy (CGT). The platform offers practical, scalable, and affordable CGT drug product development and manufacturing solutions. Over 800 organizations currently use G-Rex technology, and it is involved in the production of drugs for approximately 50% of CGT clinical trials, as well as five commercially approved CGT drugs. ScaleReady’s expertise helps companies save significant time and resources in the commercialization of CGT.
About Wilson Wolf Manufacturing Corporation
Wilson Wolf (www.wilsonwolf.com) focuses on simplifying CGT therapy research, process development, and manufacturing through its G-Rex® technology. Used worldwide in CGT applications, Wilson Wolf’s mission is to create hope for cancer patients by providing scalable, efficient bioreactors that enhance drug production.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company that supplies innovative tools and bioactive reagents to the research and clinical diagnostics communities. In collaboration with Wilson Wolf, Bio-Techne develops tailored media and cytokines for use in G-Rex® Bioreactors, supporting high-throughput closed-system manufacturing.
About CellReady™
CellReady is the world’s first G-Rex-centric contract development and manufacturing organization (CDMO), specializing in the development and manufacturing of G-Rex-based cell and gene-modified cell therapies. Offering a wide range of services, CellReady’s mission is to provide the expertise and support needed to bring hope to cancer patients through innovative, scalable cell therapy solutions.
